China Pharma Holdings Inc (CPHI) Quote

CPHI........................................................a/h

Word is maestro posse gonna light this up in PM again! 💪🏿😈👀🍿

cphi.......................................................a/h

Moves big coming 

15 million you mean?

Wow talk about nightmare earnings! Share outstanding went from 1 million to 13 million! Company in serious risk of filing bankruptcy at this point! Nothing on DED or anything else positive! Wish I never saw this garbage!

Trend is your friend!! $CPHI

.35s after hours

.31s filling loading before news drops GL if your playing & holding :D

.34s p/m

1 month left of 1st half 2024 news could drop anyday on 1 million float insiders own 86%

Quote from 2023 news —>

Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year.




2023 news below

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

Source: PR Newswire (US)
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.

According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.

This device has a utility model patent;
Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old;
In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and
The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

Cision View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-completion-of--third-party-testing-of-dry-eye-disease-therapeutic-device-302000153.html

SOURCE China Pharma Holdings, Inc.


Copyright 2023 PR Newswire

.32 chart -> https://schrts.co/NCwWJCPg

Watch for news to drop 1 mill float now after r/s in march

QUOTE
“”We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."”


after split 1-for 5 (3/6/24)
1 Million float
10 Mill o/s
Insiders own 86% per finviz*

Chart -> https://schrts.co/EjjTrTmK
Finviz -> https://finviz.com/quote.ashx?t=CPHI&p=d






News —> 11/29/23

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

Source: PR Newswire (US)
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.

According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.

This device has a utility model patent;
Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old;
In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and
The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

Cision View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-completion-of--third-party-testing-of-dry-eye-disease-therapeutic-device-302000153.html

SOURCE China Pharma Holdings, Inc.


Copyright 2023 PR Newswire

CPHI new 52 lo

No I mean days later when you look at the chart, and I'm using it on the mobile app... perhaps it's a different set up online.

But ihub on the mobile app doesn't show you the high of the day on the chart when you look back up to 3 years. It shows the Closing price.

Like I said, perhaps it's different on the desktop app

ihub doesn't show the high of day

sure it does.

https://ih.advfn.com/stock-market/AMEX/china-pharma-CPHI/stock-price

CPHI: effective March 6,2024 a one for 5 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

So far so good,no r/s today at least(usually immediately after close,4pm)

https://www.bing.com/search?q=why+do+companies+file+an+S-3+notice+of+effectiveness&qs=n&form=QBRE&sp=-1&lq=0&pq=why+do+companies+file+an+s-3+notice+of+effectiveness&sc=6-52&sk=&cvid=EC657C8D81EE4DA088E54A28A79C767C&ghsh=0&ghacc=0&ghpl=

just noticed it trades on amex exchange,thats the otc of big boards imo

always go with your gut,trusting a china ticker is like trusting a fart,sometimes you get shit on,lol

would like to take a position but somethings says WAIT

AGBA private placement closed 3 hrs ago,shares ava. to short dropping,charting bullish,looking good!!!

Personally, I think better odds on the Chinese ticker $AGBA

Makes sense, I always forget, ihub doesn't show the high of day, just the close... lol silly me...

Good luck... sometimes reverse Splits bank big... depends whose involved

1 for10 r/s was approved in dec.can be effected anytime,it could be coming after close today,i wont be holding thru close just in case

it went from lod .11 to hod .23,but yea 100m vol @.15 ave=$15m,i would expect a much bigger move from that much vol,must have been a bunch of debt paid off that day,or dark pool crooked mms,a 1 for 10 r/s was approved in dec. and it says can be effected anytime,could be effective after close,the effect today doesnt say what it is,but i wont be holding thru close today just incase

In December, they had 100 million volume, but they only moved from .10 - .13 cents... 30% is still an amazing win I guess

http://www.chinapharmaholdings.com/

maybe urine lol,the last 8k filing was a definitive material agreement for patent purchase of a psoriasis product,maybe its poop lol ,they paid 15m shares and 5m restricted ($2M) and 10% of profit for 10 years

What’s the dry eye devise a bottle of visine. CPHI

https://capedge.com/filing/1106644/9999999995-24-000463/CPHI-EFFECT ,usually comes with 8k detail filing of what effect occurred,this 13g filed yesterday, the last filing was definitive agreement of patent transfer,maybe that has taken effect> https://capedge.com/filing/1106644/0001213900-24-011587/CPHI-8K

haven't ran since nov,oversold,poked head above ma's today(hint of bullish start)with china hype lately and .10pps i think its a prime suspect for interest,and if the expected merger news hits it should do well

sales 7.78m,book .21,mkt cap 5.57m,float 21m,o/s 57m

ran to .2310 on nov 29th with 105m traded

shares ava. to short is high 800k,has dropped to zero borrow before with vol.,but who in right mind shorts from a dime

china runner starting!!!

Rock on Fish on start reeling $$$$$$

So the Taylor Swift of China now owns 15 million shares of this? https://en.wikipedia.org/wiki/Liu_Tao

So the Taylor Swift of China now owns 15 million shares of this? https://en.wikipedia.org/wiki/Liu_Tao

CPHI: Got some of this Chinese Un-Fortunate-Cookie @$0.1255 in the Post-M today, for my personal amusement. ("Mark's" mention on the Orions Board, due filings just now; even though he HATES it.)


PS: I got married AGAIN, last Sunday, in a local San Diego Atheists' Chapel! Check-out a clip from the ceremony, above!! She's a veritable DOLL, ain't she??!! We're flyin' to PALESTINE for our honeymoon!! Booked a nice suite in a Motel-6 there, in the Golan Heights, run by a Jewish buddy of mine!!

i WONDER IF THIS IS THE SAME GUY

https://www.propublica.org/article/liu-tao-trump-meeting-china-investigation
https://ih.advfn.com/stock-market/AMEX/china-pharma-CPHI/stock-news/93151163/form-sc-13g-statement-of-acquisition-of-benefici


CPHI January 2024 Shelf
EDGAR
Pending Effect

Current Raisable Amount
$16,532,168
Total Shelf Capacity
$50,000,000


https://dilutiontracker.com/app/search/CPHI?a=dbb88c

"Fake news?" Congrats to all you CPHI shareholders on your incoming 33,000 % gains!

CNN financials page analyst says "price target $45. Revenues $37M. EPS $2+."

But the NYSE stock's actually trading at 13 cents and market cap of $4M?

WTAF is true anymore?

https://money.cnn.com/quote/quote.html?symb=CPHI#:~:text=China%20Pharma%20Holdings%20Inc%20(NYSE%20American%3ACPHI)

https://twitter.com/tyrus603/status/1732100139550965843?t=DoOtwX4vmgUKX8MPn5oKtg&s=19

$CPHI ~ China Pharma Holdings Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.

Link: https://finance.yahoo.com/news/china-pharma-holdings-inc-announced-130000348.html

$$$CPHI$$$

Form_4 filing shows Li Zhilin as the owner of 15,138,063 $CPHI shares. WOW!

https://www.otcmarkets.com/filing/html?id=16995596&guid=WuJ-kahrG2lS-ch#OWNERSHIP_HTM_F1

$CPHI >>> 1Y/Daily Chart~



$$$CPHI$$$

$CPHI ~ 180day/daily Chart~



$$$CPHI$$$

$CPHI ~ China Pharma Holdings Inc @$.13
+0.0051 (+4.08%)
Volume: 2,905,839
Day Range: 0.125 - 0.142
Last Trade Time: 5:48:57 PM EST




$$$CPHI$$$

Buyout ?

45 cents works for me!